This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Centre Hospitalier Unviersitaire De Caen, Katholieke Universiteit Leuven, National Institute of Health and Medical Research. Active years: 2006-2019.
Company Filing History:
1 out of 1 
1 out of 630 
1 out of 1,853 
Years Active: 2006-2019
Title: The Innovations of Paul Declerck
Introduction
Paul Declerck is a notable inventor based in Leuven, Belgium. He has made significant contributions to the field of thrombotic disorder treatments through his innovative patents. With a total of 2 patents, his work focuses on developing bispecific inhibitors and therapeutic methods that target specific proteins involved in thrombotic conditions.
Latest Patents
One of his latest patents is titled "Dual targeting of TAFI and PAI-1." This invention discloses a bispecific inhibitor designed for treating thrombotic disorders, including acute conditions like stroke and thromboembolism. The bispecific inhibitor utilizes monoclonal antibodies that target TAFI and PAI-1, demonstrating efficacy regardless of the presence of plasminogen activators such as tissue-type plasminogen activator (tPA). Another significant patent involves therapeutic methods employing PAI-1 inhibitors and a transgenic non-human animal for screening candidate PAI-1 inhibitors. This method outlines a process for testing candidate compositions for PAI-1 inhibition activity using a transgenic non-human warm-blooded vertebrate animal that has a PAI-1 gene incorporated into its genome.
Career Highlights
Throughout his career, Paul Declerck has worked with prestigious institutions, including Vanderbilt University and Katholieke Universiteit Leuven. His research has focused on innovative approaches to address thrombotic disorders, contributing to advancements in medical treatments.
Collaborations
Paul has collaborated with notable professionals in his field, including Douglas E. Vaughan and Mesut Eren. These collaborations have further enhanced the impact of his research and innovations.
Conclusion
Paul Declerck's contributions to the field of thrombotic disorder treatments through his innovative patents highlight his role as a significant inventor. His work continues to influence the development of effective therapeutic methods.